PrEP uptake/adherence to reduce periconception HIV risk for South African women

采取/坚持 PrEP 可降低南非妇女围孕期 HIV 风险

• 批准号: 9336963
• 负责人: Lynn T Matthews
• 金额: $ 57.74万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-25 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9336963
• 关键词: AIDS prevention; Adherence; Affect; Age; Anti-Retroviral Agents; Caring; Centers for Disease Control and Prevention (U.S.); Child; Communities; Conceptions; Counseling; Couples; Data; Development; Drug Kinetics; Family; Female; Fertility; Future; Goals; Guidelines; HIV; HIV Infections; HIV risk; HIV therapy; High Risk Woman; Human immunodeficiency virus test; Incidence; Intervention; Interview; Live Birth; Measures; Motivation; Oral; Participant; Pattern; Perinatal; Pharmaceutical Preparations; Placebos; Planned Pregnancy; Plasma; Population; Pregnancy; Pregnant Women; Prevalence; Prevention; Prevention strategy; Qualitative Methods; Recruitment Activity; Reporting; Research Personnel; Resources; Risk; Risk Reduction; Safety; Sampling; Sex Behavior; Sexual Partners; Social support; South Africa; South African; Tenofovir; Testing; Time; Visit; Woman; arm; base; condoms; cost; emtricitabine; experience; follow-up; high risk; men; novel; pandemic disease; pill; placebo controlled study; pre-exposure prophylaxis; pregnant; prevent; primary outcome; promoter; public health relevance; risk perception; sex; transmission process; uptake

 DESCRIPTION (provided by applicant): In HIV-endemic settings, many HIV-uninfected women choose to conceive with an HIV-infected or unknown- serostatus partner. For a woman who cannot depend on a partner to test, initiate and adhere to ART, sex without condoms puts her at high risk of acquiring HIV and increases the risk of perinatal transmission to her child. Daily, oral TDF/FTC PrEP dramatically reduces a woman's risk of HIV-acquisition and is the only female-controlled option for reducing her risk of periconception HIV-acquisition. Understanding whether daily, oral PrEP is feasible for uninfected women seeking pregnancy is critical to reducing HIV incidence among women and their children. We propose a single-arm study to offer daily, oral PrEP for periconception use to 350 HIV-uninfected women in KwaZulu-Natal, South Africa who report personal or partner plans for pregnancy with an infected or unknown serostatus partner. Women who become pregnant on PrEP will have the option to continue PrEP during pregnancy. PrEP will be offered as part of a safer conception package inclusive of couples-based HIV counseling and testing. In Aim 1, we will evaluate the proportion of women initiating PrEP and determine factors associated with uptake. In Aim 2, we will evaluate objectively-measured PrEP adherence during periconception and pregnancy follow-up. Level, patterns, and correlates of adherence will be evaluated using plasma drug concentrations and electronic pill caps. Our primary outcome is prevalence of protective plasma tenofovir concentrations (> 40 ng/ml). We will also evaluate median adherence to dispensed pills with electronic pill caps. From formative studies in South Africa, we hypothesize that adherence to a proven intervention (TDF/FTC PrEP) for a defined risk period (periconception, pregnancy) with a clear end point (live birth) will be high (protective tenofovir concentrations at 80% of visits, adherence to >80% of prescribed pills). In Aim 3, longitudinal quantitative data and in-depth interviews with initially high- and low-adhering participants will inform our conceptual framework for periconception PrEP uptake and adherence. Placebo-controlled trials identified adherence as a major challenge to long-term PrEP use. However, women are eager for prevention strategies that allow for conception, and we hypothesize that adherence to a proven prevention strategy, for a limited time with the motivation to have a healthy child, will confer drug levels required to prevent HIV transmission. Consistent with PA11-275 "Discovery, Development, & Testing of Novel Interventions to Advance HIV Prevention and Care", this application advances combination approaches to HIV- prevention and targets a population highly affected by the pandemic. This project will determine whether daily, oral PrEP is a feasible HIV-prevention strategy for South African women who conceive with risky partners. Given the repercussions of acquiring HIV during conception and pregnancy, this is an important step towards providing a key prevention strategy to women and their children.

 描述(由申请人提供)：在艾滋病毒流行的环境中，许多未感染艾滋病毒的妇女选择与感染艾滋病毒或血清状态不明的伴侣怀孕。对于一个不能依赖伴侣进行检测、发起和坚持抗逆转录病毒治疗的女性来说，不使用避孕套的性行为会使她面临感染艾滋病毒的高风险，并增加将艾滋病毒传播给孩子的风险。每天，口服TDF/FTC PrEP极大地降低妇女感染艾滋病毒的风险，是唯一由女性控制的降低围产期艾滋病毒感染风险的选择。了解每天口服PrEP对于寻求怀孕的未感染妇女是否可行，对于降低妇女及其子女的艾滋病毒发病率至关重要。我们建议进行一项单臂研究，为南非夸祖鲁-纳塔尔的350名未感染艾滋病毒的女性提供每日口服PrEP用于围产期，她们报告个人或伴侣计划与感染或未知血清状态的伴侣怀孕。在PrEP上怀孕的妇女将可以选择在怀孕期间继续PrEP。Prep将作为更安全的受孕方案的一部分提供，包括以夫妇为基础的艾滋病毒咨询和检测。在目标1中，我们将评估启动PrEP的女性比例，并确定与摄取相关的因素。在目标2中，我们将评估客观测量的PrEP在围产期和妊娠随访期间的依从性。依从性的水平、模式和相关性将使用血浆药物浓度和电子药帽进行评估。我们的主要结果是保护性血浆替诺福韦浓度(&gt；40 ng/ml)的流行。我们还将评估带有电子药帽的处方药丸的中位数依从性。从南非的形成性研究中，我们假设，在明确的终点(活产)的确定的风险期(围产期、妊娠期)内，坚持经过验证的干预措施(TDF/FTC PrEP)将是高的(80%的就诊患者的保护性替诺福韦浓度，80%的处方药的依从性)。在目标3中，纵向定量数据和对最初高粘附性和低粘附性参与者的深入访谈将为我们提供关于围观PrEP吸收和坚持的概念框架。安慰剂对照试验发现，长期使用PrEP的主要挑战是依从性。然而，妇女渴望能够怀孕的预防战略，我们假设，在有限的时间内坚持一个经过验证的预防战略，并有动力生一个健康的孩子，将提供预防艾滋病毒传播所需的药物水平。与PA11-275“发现、开发和测试促进艾滋病毒预防和护理的新干预措施”相一致，该应用程序推进了艾滋病毒预防的组合方法，并针对受大流行高度影响的人群。该项目将确定对于与有风险的伴侣怀孕的南非妇女来说，每日口服PrEP是否是一种可行的艾滋病毒预防策略。鉴于在怀孕和怀孕期间感染艾滋病毒的后果，这是朝着向妇女及其子女提供关键预防战略迈出的重要一步。